Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
463 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape. Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resistant prostate cancer is characterized by rising prostate specific antigen (PSA) with a low testosterone and is associated with poor prognosis. mHRPC arises when prostate cancer becomes non-responsive to hormone therapy and spreads to neighboring tissues or to other parts of the body such as the bones. Some of the most important predisposing factors for mHRPC include increasing age, environmental stress and genetic factors. Symptoms of mHRPC may include lethargy, paraplegia, bone pain, lower back or pelvic pain and weight loss. It may be controlled by hormonal therapy, radiation therapy or chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 6, 37, 20 and 19 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively.Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 8 Therapeutics Development 9 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 11 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 15 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 16 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 19 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 25 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 26 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 87 Drug Profiles 101 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 433 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 438 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 441 Appendix 452
List of Tables
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016 19 Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Number of Products under Development by Companies, H2 2016 (Contd..2) 23 Number of Products under Development by Companies, H2 2016 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2016 25 Comparative Analysis by Late Stage Development, H2 2016 26 Comparative Analysis by Clinical Stage Development, H2 2016 27 Comparative Analysis by Early Stage Development, H2 2016 28 Products under Development by Companies, H2 2016 29 Products under Development by Companies, H2 2016 (Contd..1) 30 Products under Development by Companies, H2 2016 (Contd..2) 31 Products under Development by Companies, H2 2016 (Contd..3) 32 Products under Development by Companies, H2 2016 (Contd..4) 33 Products under Development by Companies, H2 2016 (Contd..5) 34 Products under Investigation by Universities/Institutes, H2 2016 35 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science SA, H2 2016 36 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc, H2 2016 37 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 38 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Advaxis Inc, H2 2016 39 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ambrx Inc, H2 2016 40 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc, H2 2016 41 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 42 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 43 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ArQule Inc, H2 2016 44 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 45 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arvinas Inc, H2 2016 46 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016 47 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016 48 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 49 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 50 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 51 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016 52 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 53 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 54 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celgene Corp, H2 2016 55 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016 56 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016 57 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016 58 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 59 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Curevac AG, H2 2016 60 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016 61 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016 62 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte Inc, H2 2016 63 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016 64 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 65 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016 66 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016 67 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 68 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx Inc, H2 2016 69 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 70 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 71 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2016 72 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MedImmune LLC, H2 2016 73 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation Inc, H2 2016 74 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MEI Pharma Inc, H2 2016 75 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 76 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corp, H2 2016 77 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2016 78 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H2 2016 79 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 80 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 81 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc, H2 2016 82 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 83 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Selexel, H2 2016 84 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio as, H2 2016 85 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc, H2 2016 86 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 87 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 88 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro Inc, H2 2016 89 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 90 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tiltan Pharma Ltd, H2 2016 91 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals Inc, H2 2016 92 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 93 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by UbiVac LLC, H2 2016 94 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd, H2 2016 95 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Zenith Capital Corp, H2 2016 96 Assessment by Monotherapy Products, H2 2016 97 Number of Products by Stage and Target, H2 2016 99 Number of Products by Stage and Mechanism of Action, H2 2016 104 Number of Products by Stage and Route of Administration, H2 2016 108 Number of Products by Stage and Molecule Type, H2 2016 110 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2016 443 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H2 2016 444 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H2 2016 445 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H2 2016 446 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..4), H2 2016 447 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2016 448 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H2 2016 449 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..2), H2 2016 450
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
